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31 might be involved in the molecular
switch from proliferation to differentia-
tion needs to be determined.
In conclusion, in vitro studies ana-
lyzing the effects of the previously
unknown cytokine IL-31 on epidermal
keratinocytes should consider the
variation of IL-31Ra expression, which
depends on the status of cellular differ-
entiation and the influence of pro-
inflammatory cytokines. Further clinical
studies and highly specific mAbs are
necessary to assess the impact of these
findings in vivo.
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TO THE EDITOR
Imiquimod, an imidazoquinoline im-
mune response modifier, has been ap-
proved for the topical treatment of
anogenital warts and has shown efficacy
in superficial basal cell carcinomas and
actinic keratoses (Beutner et al., 1999;
Ulrich et al., 2006). When applied
topically, it induces strong T-lymphocy-
tic infiltrates due to its binding to Toll-
like receptor 7 (TLR7) and stimulation of
various cytokines (Hemmi et al., 2002).
It has the ability to enhance both the
innate and cellular immune responses by
acting on a number of cell types (Sauder
2000; Dahl 2002).
The development of vitiligo-like
hypopigmentary lesions associated with
topical imiquimod has been reported
(Brown et al., 2005; Stefanaki et al.,
2006). Taking into consideration those
actions, imiquimod may have acted as a
triggering factor in an individual suscep-
tible to the development of vitiligo. If
Abbreviations: G3PDH, glyceraldehyde-3-phosphate dehydrogenase; MITF, microphthalmia-associated
transcription factor; siRNA, small interfering RNA; TLR, Toll-like receptor
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vitiligo is a cytotoxic T-lymphocyte-
mediated autoimmune disease, then
imiquimod could contribute to the elim-
ination of melanocytes by inducing
acquired immunity through the induc-
tion of cytokines (Ongenae et al., 2003).
The main actions of melanin in
human skin appear to be attenuation
of ultraviolet penetration to the skin and
protection of the skin against sun-
induced damage (Slominski et al.,
2004). Additional properties of melanin
may include bactericidal potential
via the production of orthoquinones
(Slominski et al., 2004). Indeed, melano-
cytes are not simply pigment-producing
cells but also a component of the skin’s
immune defense system (Lu et al.,
2002). Cultured human melanocytes
can present peptide antigen and func-
tion as target cells for T-cell-mediated
cytotoxicity, suggesting a possible re-
lationship with hypopigmentary disor-
ders (Le Poole et al., 1993). We
previously reported that normal human
melanocytes express TLR4 and that its
ligand directly inhibits cell growth and
induces melanogenesis of cells (Ahn
et al., 2008). Therefore, it is possible for
melanocytes to be destroyed as targets
of the immune system. In preliminary
studies, we found that normal human
melanocytes express TLR7. In this
study, we analyzed the mode of action
of imiquimod, including inhibition of
melanogenesis through TLR7.
To investigate whether TLR7 is con-
stitutively expressed in cultured normal
human melanocytes, we performed
reverse transcription-PCR, immunocy-
tochemistry, and western blot analysis.
The primer sequences used were as
follows: forward primer TCCAGTGTC
TAAAGAACCTGG and reverse primer
TGGTAAATATACCACACATCCC (Lebre
et al., 2007). The reverse transcription-
PCR studies indicated that human
melanocytes express TLR7 mRNA
(Figure 1a). Immunocytochemical stain-
ing showed immunoreactivity for anti-
TLR7 protein in human melanocytes
(Figure 1b). The expression of TLR7
protein was further confirmed by western
blot analysis (Figure 1c).
To investigate the functional role of
TLR7 in melanocytes, cells were treated
with imiquimod, a ligand of TLR7, for
5 days. The direct addition of 1 and
10 mg ml1 (41.6 mM) imiquimod re-
duced melanin contents to 90 or 76%
(mean±SD of control, n¼ 5) of the
control cells (100%), respectively
(Figure 2a). To verify the molecular
basis of imiquimod on melanogenesis,
we investigated the expression of
microphthalmia-associated transcription
factor (MITF) and tyrosinase protein,
which has been demonstrated to be a
hallmark of melanogenesis (Goding,
2000; Park et al., 2006). As shown in
Figure 2b and c, imiquimod reduced
the expression of MITF and tyrosinase
protein. Stimulation of melanocytes
with imiquimod inhibited melanocyte
growth (Figure 2d). We then investi-
gated whether this inhibitory effect is
dependent on TLR7 using TLR7-specific
small interfering RNA (siRNA). TLR7
mRNA and protein were nearly elimi-
nated in melanocytes transfected
with TLR7-specific siRNA (Figure 2e
and f). When melanocytes were
preincubated with TLR7 siRNA
(200 nM) for 20 minutes before the
addition of imiquimod (10 mg ml1),
the inhibition of melanin contents
(Figure 2g) and cell growth (Figure 2h)
was abrogated. These results suggest
that imiquimod may modulate cell
growth and melanogenesis by a TLR7-
dependent mechanism.
The present study demonstrates that
normal human melanocytes express
TLR7. This receptor may be functional,
as stimulation of melanocytes with
imiquimod leads to decreased tyrosi-
nase and MITF expression and is
accompanied by decreased pigmenta-
tion. Imiquimod also inhibits the
growth of melanocytes. These effects
appear to be TLR-dependent, as siRNA
TLR7 reverse the inhibitory effects of
imiquimod on melanogenesis and cell
proliferation. Metcalf et al. (2007)
demonstrated antiaging effects of topi-
cal imiquimod in lentigo maligna pa-
tients. The authors also mentioned an
apparent reduction in melanocyte den-
sity in treated skin. Therefore, it is
speculated that melanocytes in the skin
may express TLR7 and that imiquimod
may modulate skin pigmentation
through TLR7.
Imiquimod downregulated the ex-
pression of MITF, a key protein regulat-
ing the survival of melanocytes as well
as melanogenesis (Goding, 2000; Du
et al., 2003; Park et al., 2006). Loss of
function and the reduced expression
of MITF frequently result in the loss of
melanocytes, suggesting that survival
of melanocytes depends on the proper
function and level of MITF expression.
It was reported that the reduction in
MITF at the edge of the vitiligo epider-
mis in vivo may be associated with the
loss of melanocytes in the lesional
epidermis (Kitamura et al., 2004). MITF
expression in melanocytes is closely
associated with their apoptosis as a
result of the downregulation of the
suppressive apoptotic molecule Bcl-2
(McGill et al., 2002). TLR7 activation
may lead to apoptosis (Meyer et al.,
500 bp
M TLR7 GAPDH
174 kDa
117 kDa TLR7
TLR 7
Control
Figure 1. TLR7 is expressed in human melanocytes. (a) Expression of TLR7 was assessed by RT-PCR, and
an RT-PCR product corresponding to TLR7 (lane 2) was obtained. M indicates the molecular weight
marker, and lane 3 represents GAPDH. Using anti-TLR7 antibody, their protein expression was detected
by immunocytochemistry (b) and western blotting (c). Negative controls were produced by applying
normal rabbit serum before the primary antibody. Original magnification 200.
244 Journal of Investigative Dermatology (2009), Volume 129
HY Kang et al.
Toll-Like Receptor 7 in Human Melanocytes
2003). Induction of apoptosis by
imiquimod in human epithelial cell
lines and keratinocytes, as well as in
mouse fibroblasts, was reported,
although inferences as to which recep-
tors mediate imiquimod-induced cell
death are speculative (Meyer et al.,
2003). Therefore, it is likely that
the mode of action of imiquimod
includes the triggering of apoptosis that
results in the loss of melanocytes
and may be related to the downregula-
tion of MITF. This should be further
studied.
The overall findings in this study
provide in vitro evidence demonstrating
a direct effect of imiquimod on
melanocytes and may reveal a possible
mechanism of imiquimod-induced
vitiligo.
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Figure 2. Imiquimod inhibits melanogenesis and cell growth through TLR7-mediated mechanisms. (a) Human melanocytes were treated with imiquimod
(1–10 mg ml1) for 5 days. Melanin content was determined by measuring the absorbance at 490 nm of cell lysate. The values indicate the mean of five
independent experiments±SD. *Po0.01. Melanocytes were stimulated with 1 mg ml1 of imiquimod at the times indicated. Whole-cell lysates were then
subjected to western blot analysis with antibodies against microphthalmia-associated transcription factor (b) and tyrosinase (c). (d) Cell number was determined
with a Coulter counter. The values indicate the mean of five independent experiments±SD. *Po0.05. TLR7 mRNA (e) and protein (f) were nearly eliminated in
melanocytes transfected with TLR7-specific siRNA. Melanocytes were preincubated with siRNA of TLR7 for 20 minutes before the addition of imiquimod
(10mg ml1). The melanin content (g) and cell numbers (h) were determined. The values indicate the mean of three independent experiments±SD. *Po0.01.
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Merkel Cell Polyomavirus Is More Frequently Present
in North American than Australian Merkel Cell
Carcinoma Tumors
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TO THE EDITOR
Merkel cell carcinoma (MCC) is an
increasingly common neuroendocrine
cancer of the skin. MCC is an aggres-
sive malignancy that is a significant
cause of nonmelanoma skin cancer
deaths. Although the genetics of MCC
are poorly characterized, it is well
established that MCC is associated with
advanced age and UV exposure. MCC
is also linked to immune suppression;
8% of MCC patients are chronically
immunosuppressed, which is a 16-fold
overrepresentation (Heath et al., 2008).
In particular, MCC is linked to T-cell
dysfunction associated with malignant,
infectious, and iatrogenic causes (Miller
and Rabkin, 1999; Engels et al., 2002;
Heath et al., 2008).
Recently, Feng et al. (2008), de-
scribed a novel polyomavirus that is
associated with MCC. This virus,
named Merkel cell polyomavirus
(MCPyV), was present in 8 of 10 MCC
tumors as compared to 1 of 15 normal
skin controls. Several clues suggest a
possible functional role for this virus in
cancer. MCPyV shares key features with
the SV40 polyomavirus, an oncogenic
virus in animals, such as the predicted
ability of a viral T antigen protein to
bind and inactivate the tumor suppres-
sor Rb. Furthermore, MCPyV DNA was
reported to be monoclonally integrated
into six of the tumors, which implies
that viral integration was an early event
in MCC carcinogenesis and occurred
before tumor expansion.
See related commentary on pg 9
Abbreviations: MCC, Merkel cell carcinoma; MCPyV, Merkel cell polyomavirus
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Merkel cell polyomavirus DNA in MCC tumors
